636 related articles for article (PubMed ID: 12805374)
1. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
Gavrilova O; Haluzik M; Matsusue K; Cutson JJ; Johnson L; Dietz KR; Nicol CJ; Vinson C; Gonzalez FJ; Reitman ML
J Biol Chem; 2003 Sep; 278(36):34268-76. PubMed ID: 12805374
[TBL] [Abstract][Full Text] [Related]
2. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.
Chao L; Marcus-Samuels B; Mason MM; Moitra J; Vinson C; Arioglu E; Gavrilova O; Reitman ML
J Clin Invest; 2000 Nov; 106(10):1221-8. PubMed ID: 11086023
[TBL] [Abstract][Full Text] [Related]
3. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Murakami K; Tobe K; Ide T; Mochizuki T; Ohashi M; Akanuma Y; Yazaki Y; Kadowaki T
Diabetes; 1998 Dec; 47(12):1841-7. PubMed ID: 9836514
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.
Memon RA; Tecott LH; Nonogaki K; Beigneux A; Moser AH; Grunfeld C; Feingold KR
Endocrinology; 2000 Nov; 141(11):4021-31. PubMed ID: 11089532
[TBL] [Abstract][Full Text] [Related]
5. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.
Norris AW; Chen L; Fisher SJ; Szanto I; Ristow M; Jozsi AC; Hirshman MF; Rosen ED; Goodyear LJ; Gonzalez FJ; Spiegelman BM; Kahn CR
J Clin Invest; 2003 Aug; 112(4):608-18. PubMed ID: 12925701
[TBL] [Abstract][Full Text] [Related]
6. Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
Duan SZ; Usher MG; Foley EL; Milstone DS; Brosius FC; Mortensen RM
Diabetologia; 2010 Jul; 53(7):1493-505. PubMed ID: 20401461
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
[TBL] [Abstract][Full Text] [Related]
8. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Bedoucha M; Atzpodien E; Boelsterli UA
J Hepatol; 2001 Jul; 35(1):17-23. PubMed ID: 11495036
[TBL] [Abstract][Full Text] [Related]
9. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
Savage DB; Tan GD; Acerini CL; Jebb SA; Agostini M; Gurnell M; Williams RL; Umpleby AM; Thomas EL; Bell JD; Dixon AK; Dunne F; Boiani R; Cinti S; Vidal-Puig A; Karpe F; Chatterjee VK; O'Rahilly S
Diabetes; 2003 Apr; 52(4):910-7. PubMed ID: 12663460
[TBL] [Abstract][Full Text] [Related]
10. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.
Albrektsen T; Frederiksen KS; Holmes WE; Boel E; Taylor K; Fleckner J
Diabetes; 2002 Apr; 51(4):1042-51. PubMed ID: 11916924
[TBL] [Abstract][Full Text] [Related]
11. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs).
Staels B; Schoonjans K; Fruchart JC; Auwerx J
Biochimie; 1997; 79(2-3):95-9. PubMed ID: 9209702
[TBL] [Abstract][Full Text] [Related]
12. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
Fukui Y; Masui S; Osada S; Umesono K; Motojima K
Diabetes; 2000 May; 49(5):759-67. PubMed ID: 10905484
[TBL] [Abstract][Full Text] [Related]
13. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects.
Auwerx J; Schoonjans K; Fruchart JC; Staels B
J Atheroscler Thromb; 1996; 3(2):81-9. PubMed ID: 9226459
[TBL] [Abstract][Full Text] [Related]
14. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Camp HS; Li O; Wise SC; Hong YH; Frankowski CL; Shen X; Vanbogelen R; Leff T
Diabetes; 2000 Apr; 49(4):539-47. PubMed ID: 10871190
[TBL] [Abstract][Full Text] [Related]
15. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.
He W; Barak Y; Hevener A; Olson P; Liao D; Le J; Nelson M; Ong E; Olefsky JM; Evans RM
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15712-7. PubMed ID: 14660788
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression.
Kelly LJ; Vicario PP; Thompson GM; Candelore MR; Doebber TW; Ventre J; Wu MS; Meurer R; Forrest MJ; Conner MW; Cascieri MA; Moller DE
Endocrinology; 1998 Dec; 139(12):4920-7. PubMed ID: 9832429
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
18. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
Dallaire P; Bellmann K; Laplante M; Gélinas S; Centeno-Baez C; Penfornis P; Peyot ML; Latour MG; Lamontagne J; Trujillo ME; Scherer PE; Prentki M; Deshaies Y; Marette A
Diabetes; 2008 Aug; 57(8):1999-2011. PubMed ID: 18458147
[TBL] [Abstract][Full Text] [Related]
19. A mutation in the peroxisome proliferator-activated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice.
Olswang Y; Cohen H; Papo O; Cassuto H; Croniger CM; Hakimi P; Tilghman SM; Hanson RW; Reshef L
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):625-30. PubMed ID: 11792850
[TBL] [Abstract][Full Text] [Related]
20. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.
Chou CJ; Haluzik M; Gregory C; Dietz KR; Vinson C; Gavrilova O; Reitman ML
J Biol Chem; 2002 Jul; 277(27):24484-9. PubMed ID: 11994294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
